Stay updated on Setmelanotide in BBS and AS for Obesity Clinical Trial
Sign up to get notified when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.

Latest updates to the Setmelanotide in BBS and AS for Obesity Clinical Trial page
- CheckyesterdayChange DetectedThe page has undergone significant content removal, particularly regarding the details of a pivotal Phase 3 study for setmelanotide in treating obesity related to Bardet Biedl Syndrome and Alström Syndrome, including eligibility criteria and study design. The only notable addition is the mention of Bardet Biedl Syndrome and a revision number.SummaryDifference30%
- Check8 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check52 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check66 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check73 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Setmelanotide in BBS and AS for Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Setmelanotide in BBS and AS for Obesity Clinical Trial page.